Cardiovascular and Renal Morbidity in Takayasu Arteritis: A Population-Based Retrospective Cohort Study From the United Kingdom.

Goel, Ruchika, Chandan, Joht Singh, Thayakaran, Rasiah, Adderley, Nicola J, Nirantharakumar, Krishnarajah and Harper, Lorraine (2021) Cardiovascular and Renal Morbidity in Takayasu Arteritis: A Population-Based Retrospective Cohort Study From the United Kingdom. Arthritis & rheumatology (Hoboken, N.J.), 73 (3). pp. 504-511. ISSN 2326-5205. This article is available to all UHB staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their UHB Athens login IDs.

Full text not available from this repository.
Official URL: https://onlinelibrary.wiley.com/doi/10.1002/art.41...

Abstract

OBJECTIVE

Cardiovascular disease (CVD) is a major complication and cause of mortality in Takayasu arteritis (TAK), but population-based controlled studies from the UK are lacking. We undertook the present study to investigate the frequency of morbidity and mortality related to CVD, as well as to cerebrovascular and kidney disease, among patients with TAK in the UK.

METHODS

Yearly cohort and cross-sectional studies were performed from 2000 to 2017 to estimate annual incidence and prevalence, respectively, of TAK. Using a UK primary care database (IQVIA Medical Research Data), an open retrospective matched cohort study was conducted to estimate risk of hypertension, diabetes, cardiovascular morbidity, chronic kidney disease (CKD), and all-cause mortality in TAK. Risk (adjusted hazard ratio [HR]) of the assessed comorbidities among patients with TAK compared to age- and sex-matched controls was estimated. Changes in medication prescription over time were examined in both groups.

RESULTS

One hundred forty-two patients with TAK (median age 53.4 years [interquartile range 33.8-70.7]) and 1,371 matched controls were included. The annual incidence and prevalence of TAK were 0.8 per million and 7.5 per million respectively. All-cause mortality was increased in TAK (adjusted HR 1.88 [95% confidence interval 1.29-2.76]). Patients with TAK had an increased risk of developing ischemic heart disease, stroke/transient ischemic attack, combined CVD, and peripheral vascular disease compared to controls, but no increase in risk of hypertension, CKD, heart failure, or diabetes. Only ~50% of patients with TAK requiring secondary CVD prevention were prescribed statins or antiplatelet agents within 1 year after study entry.

CONCLUSION

Cardiovascular morbidity was increased among patients with TAK receiving primary care services in the UK. Treatment with statins and antiplatelet agents in these patients was suboptimal.

Item Type: Article
Additional Information: This article is available to all UHB staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their UHB Athens login IDs.
Subjects: WD Diseases and disorders of systemic, metabolic or environmental origin > WD811 Rheumatology
WG Cardiovascular system. Cardiology
WJ Urogenital system. Urology
Divisions: Ambulatory Care > Rheumatology
Emergency Services > Renal
Related URLs:
Depositing User: Mrs Noomi Tyholdt-Pidgley
Date Deposited: 05 Aug 2021 10:03
Last Modified: 05 Aug 2021 10:03
URI: http://www.repository.uhblibrary.co.uk/id/eprint/4534

Actions (login required)

View Item View Item